Cancer-related distress in unselected women with newly diagnosed breast or ovarian cancer undergoing BRCA1/2 testing without pretest genetic counseling by Hoberg-Vetti, H. et al.
PDF hosted at the Radboud Repository of the Radboud University
Nijmegen
 
 
 
 
The following full text is a publisher's version.
 
 
For additional information about this publication click this link.
http://hdl.handle.net/2066/202775
 
 
 
Please be advised that this information was generated on 2019-12-04 and may be subject to
change.
Full Terms & Conditions of access and use can be found at
https://www.tandfonline.com/action/journalInformation?journalCode=ionc20
Acta Oncologica
ISSN: 0284-186X (Print) 1651-226X (Online) Journal homepage: https://www.tandfonline.com/loi/ionc20
Cancer-related distress in unselected women
with newly diagnosed breast or ovarian cancer
undergoing BRCA1/2 testing without pretest
genetic counseling
Hildegunn Høberg-Vetti, Geir Egil Eide, Elen Siglen, Wenche Listøl, Marianne
Tveit Haavind, Nicoline Hoogerbrugge & Cathrine Bjorvatn
To cite this article: Hildegunn Høberg-Vetti, Geir Egil Eide, Elen Siglen, Wenche Listøl,
Marianne Tveit Haavind, Nicoline Hoogerbrugge & Cathrine Bjorvatn (2019) Cancer-related
distress in unselected women with newly diagnosed breast or ovarian cancer undergoing
BRCA1/2 testing without pretest genetic counseling, Acta Oncologica, 58:2, 175-181, DOI:
10.1080/0284186X.2018.1502466
To link to this article:  https://doi.org/10.1080/0284186X.2018.1502466
© 2018 The Author(s). Published by Informa
UK Limited, trading as Taylor & Francis
Group.
View supplementary material 
Published online: 18 Oct 2018. Submit your article to this journal 
Article views: 840 View Crossmark data
ORIGINAL ARTICLE
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ABSTRACT
Background: Genetic testing is increasing in patients newly diagnosed with cancer. This study investi-
gated the levels, course and predictors of cancer-related distress, defined as intrusion and avoidance,
in women undergoing BRCA1/2 testing without pretest genetic counseling shortly after a diagnosis of
breast or ovarian cancer.
Material and methods: Unselected for family history or age, 259 women with breast cancer and 50
women with ovarian cancer, underwent BRCA1/2 testing shortly after diagnosis. Cancer-related distress
was measured with the Impact of Event Scale before and after genetic testing. In order to identify predic-
tors of distress, the subscale scores were regressed on baseline predictor variables including sociodemo-
graphic and medical variables, perceived social support, and decisional conflict regarding genetic testing.
Results: The mean levels of intrusion and avoidance were in the moderate range both before and
after genetic testing with a statistically significant decline during follow-up. Younger age, shorter time
since diagnosis, lower levels of social support, and a diagnosis of ovarian cancer predicted higher lev-
els of both intrusion and avoidance. In addition, higher levels of decisional conflict and living with a
partner predicted higher levels of intrusion.
Conclusions: Women having genetic testing shortly after a diagnosis of breast or ovarian cancer had a
moderate mean level of cancer-related distress, which decreased with time. Health personnel offering
genetic testing to newly diagnosed women with breast or ovarian cancer should be aware of the poten-
tial predictors for increased cancer-related distress identified in this study: younger age, less perceived
social support, higher levels of decisional conflict regarding genetic testing, and living with a partner.
ARTICLE HISTORY
Received 6 May 2018
Accepted 15 July 2018
Background
Genetic testing has become increasingly important in
patients diagnosed with breast or ovarian cancer in recent
years, as the presence of germline variants not only predicts
a high risk of breast and ovarian cancer, but also gives an
opportunity for personalized cancer treatment. After the
introduction of poly-(ADP-ribose) polymerase (PARP) inhibi-
tors for treatment of ovarian cancer in BRCA1/2 mutation car-
riers, diagnostic genetic testing of patients with ovarian
cancer has been implemented in routine clinical practice in
several countries [1–3]. Although less established, similar pro-
cedures are gradually introduced in breast cancer clinics,
since decisions regarding surgery and neoadjuvant chemo-
therapy might be directed by BRCA1/2 carrier status [4–6].
This new approach often implies that the genetic test is
performed a short time after diagnosis, without traditional
pretest genetic counseling or risk assessment. While previously
cancer-related distress has been thoroughly investigated in
persons receiving traditional genetic counseling for hereditary
cancer [7–10], less is known about the cancer-related distress
in women newly affected with breast or ovarian cancer who
are offered genetic testing regardless of age and family his-
tory, and who undergo genetic testing without pretest genetic
counseling. In contrast to women seeking genetic counseling
because of a suspicious family history of hereditary breast and
ovarian cancer, the women who are tested as part of the rou-
tine diagnostic work-up in a cancer clinic may be less aware
of the possibility that their cancer can have a hereditary cause,
and thus be less prepared for a decision making process
regarding genetic testing. Obviously, receiving a potential
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life-threatening cancer diagnosis is associated with significant
distress [11–14]. Concern has been raised that introducing
genetic testing shortly after diagnosis would impose an add-
itional psychological burden for women in this stressful situ-
ation [15], but so far, the evidence does not support this
concern [16].
High levels of distress interfere with the patients’ ability to
perceive important information given by health personnel [17]
and may constitute an obstacle for understanding the conse-
quences of genetic testing [18]. More attention should there-
fore be drawn to the patients with higher levels of distress.
We define distress as intrusive thoughts and avoidance
responses in this study. Intrusion and avoidance are often
associated with post-traumatic stress disorder (PTSD), but are
also studied as reactions to actual or possible threatening
events without implicating the status of a PTSD-diagnosis
[8,9], as in this article. Intrusion symptoms include unbidden
thoughts and images both awake and during sleep, waves of
overwhelming feelings of fear and repetitive behavior.
Avoidance responses include denial of the meaning and con-
sequences of the threatening event, blunted sensation, emo-
tional numbness, and attempts to block out unpleasant
feelings and memories [19].
The relatively low correlation between stressful life events
on one hand, and adverse outcome on the other, has stimu-
lated the search for moderating variables [20,21], and social
support has a central position in this research. To seek social
support seems to be one of the most successful coping strat-
egies and is often associated with favorable health outcome
[22,23]. One theory, ‘the buffer theory’, states that social sup-
port protects against the potential pathogenic effects of
stressful life events, and that this protective property is acti-
vated when needed, e.g., when a person is diagnosed with
cancer and/or is undergoing genetic testing [20,24].
While some people find it easy to make a choice about
genetic testing, others have stronger ambivalence toward
this. Women who are newly diagnosed with breast or ovar-
ian cancer are often overwhelmed with information and
choices they have to make [18]. Underlying decisional con-
flict regarding genetic testing may have an impact on the
experienced distress for these women.
There are some well-described predictors of psychological
distress among cancer patients, e.g., young age and short
time since cancer diagnosis, while other predictors have
shown more ambiguous effects in different studies, e.g., edu-
cational level, employment status, marital status, and cancer
type [13,14,25–27].
The aim of this study was to document the level, course
and predictors of cancer-related distress, in patients under-
going genetic testing a short time after the diagnosis of
breast- or ovarian cancer.
Material and methods
Study design and participants
The patients participated in a prospective multi-site study
in which genetic testing for pathogenic BRCA1/2 variants
and familial cancer risk assessment were offered to all
women newly diagnosed with breast or ovarian cancer,
the DNA-BONus study. The study protocol and the results of
the genetic testing have been published in details elsewhere
[28]. All patients with newly diagnosed breast or ovarian can-
cer, unselected for age and family history, were consecutively
invited to participate, from September 2012 to April 2015.
The participants could choose to participate only in the gen-
etic testing study, in an associated psychosocial study, or
both. This article presents data exclusively from patients par-
ticipating in the psychosocial study. The participants did not
receive genetic counseling prior to testing, but were given
written information about hereditary breast and ovarian
cancer in addition to brief information from their treating
physician or nurse. The genetic test result was given to the
patient in a letter from a genetic counselor if the test result
was normal and there was no indication for further genetic
testing. Patients who tested positive for a BRCA1/2 mutation,
or had a personal or family history suspicious of elevated
familial cancer risk, received a phone call from a genetic
counselor with information about the result and were invited
to a post-test face-to-face genetic counseling session.
The first questionnaire in the psychosocial sub study was
given to the participants along with the invitation to the
study (T1). The second and third questionnaires were mailed
to the participants 1 week (T2) and 6 months (T3) after dis-
closure of the BRCA1/2 test result, respectively.
The study protocol was approved by the Regional
Committee for Medical and Health research Ethics (REK Vest
2012-62).
Study measurements
Clinical and sociodemographic variables
Self-reported family history was retrieved from all partici-
pants in the DNA-BONus study through a structured written
questionnaire linked to the blood sampling for genetic test-
ing [28]. Clinical information was collected from the partic-
ipants’ medical files. Questions about education level,
biological children, cohabitation, and employment status
were included in the first questionnaire (T1).
Subjective distress
Subjective distress was measured with the Impact of Event
Scale (IES-15) [19]. This is a 15-item questionnaire comprising
two subscales: intrusion thoughts (IES-I), which includes
seven items and is scored from 0 to 35, and avoidance
behavior (IES-A), which consists of eight items, and is scored
from 0 to 40. The scale was developed to measure current
stress reactions after any specific traumatic event [19]. In the
present study, ‘cancer diagnosis’ was defined as the specific
event. The sub-scale scores are considered low in the range
of 0–8, moderate at 9–19 and severe at 20 and above [19].
Social support
The concept of perceived social support was measured by
the version of the Interpersonal Support Evaluation List (ISEL)
used by King and colleagues, which consists of 30 items that
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are answered with a score from 1 to 4 [7,29]. The average
sum score for each participant was used.
Decisional conflict
To measure the participant’s ambivalence toward making a
choice of undergoing BRCA1/2 genetic testing we used the
Decisional Conflict Scale (DCS) [30,31]. In the DCS, 16 items
are scored from 0 to 4, where three dimensions of decisional
conflict are measured: uncertainty about selection of alterna-
tives (three items), specific factors contributing to uncertainty
(nine items), and perceived effectiveness of decision making
(four items). Higher scores indicate higher levels of decisional
conflict. The sum score of all items was converted to a 0–100
scale, where total scores below 25 are associated with low
level of decisional conflict and scores above 37.5 are associ-
ated with problems in implementing decisions [31].
Statistical methods
Missing values were replaced by the respondent’s own aver-
age score for each questionnaire if at least 60% of the items
were filled in by the respondent. Descriptive statistics were
used to describe the sociodemographic, clinical and psycho-
logical variables, reporting the mean values, median values,
standard deviation (SD), standard error of means (SEM),
range and proportions. Paired sample t-tests and paired
Wilcoxon–Mann–Whitney tests were used to compare
changes in IES scores between the different time points.
To identify the characteristics related to the levels of IES-I
and IES-A and to test the changes of IES-I and IES-A over
time, the subscale scores were regressed on the baseline pre-
dictor variables using mixed linear modeling. The mixed linear
model uses all available data, and can account for correlations
between repeated measurements on the same subjects and
has sufficient flexibility to model time effects [32]. All predic-
tors were entered into the mixed linear models to assess both
main effects and possible interactions with time. The regres-
sion analyses were run backwards stepwise, both with and
without interaction with time. The significance level was set at
.05 for all statistical tests, and results were reported as esti-
mates with 95% confidence intervals. All statistical analyses
were performed using IBM Statistical Package for the Social
Sciences (SPSS, version 24.0) (SPSS Inc., Chicago, IL).
Results
Study sample
Of 772 eligible women in the DNA-BONus study, 403 (52.2%)
underwent genetic testing and 309 (40.0%) gave consent for
the psychosocial sub study: 259 women diagnosed with
breast cancer and 50 women diagnosed with ovarian cancer.
The mean age of the participants was 56.1 years (range:
24–89 years). The mean time from diagnosis to returning the
first questionnaire (T1) was 45 (median: 26) days for patients
with breast cancer and 156 (median: 76) days for patients
with ovarian cancer. On average, participants returned T1
two days before blood sampling for the genetic test. Cancer
treatment was initiated for 256 patients before T1, 31 partici-
pants had not started cancer treatment before T1, and treat-
ment status was unknown for 22 participants at T1. The
sociodemographic and clinical characteristics of the study
sample are provided in detail in Table 1.
Level of intrusion (IES-I) and avoidance (IES-A) before
and after genetic testing
Table 2 show the mean levels of IES-I and IES-A scores at the
three measurement points. The mean IES-I score was 14.6
(median 14.0) at T1 and decreased statistically significantly to
12.1 (median 9.0) at T2 (p< .001) and with a further statis-
tical significant decrease to 9.7 (median 7.0) at T3 (p< .001).
The overall decrease from T1 to T3 was 5.2, which corre-
sponds to 14.9% of the total IES-I scale (0–35). The mean
IES-A score was 12.7 (median 11.0) at T1, decreased statistic-
ally significantly to 10.2 (median 8.0) at T2 (p< .001), but
with no further statistical significant decrease from T2 to T3
(mean score 9.7, median 8.0). The overall decrease in IES-A
score from T1 to T3 was 3.0, 7.5% of the total IES-A scale
(0–40). At inclusion nearly one-third and one-fourth of the
patients, respectively, had IES-I and IES-A scores indicating a
severe stress response, Table 2. At T3 the proportions of
patients with scores in the severe range were reduced to
14.0 and 16.0% for IES-I and IES-A, respectively, Table 2.
Mixed linear models for intrusion and avoidance
The results of the mixed linear regression analyses for IES-I
and IES-A scores are given in Table 3. After backward step-
wise selection, the final model showed that younger age was
a predictor of higher IES-I, i.e., for each 10 years decrease in
age the mean value of IES-I score increased with 1.80,
Table 3. Additional predictors of higher levels of IES-I were
shorter time since diagnosis, lower level of perceived social
support, higher level of decisional conflict regarding the gen-
etic test, diagnosis of ovarian cancer and living with a part-
ner. Higher levels of IES-A was associated with younger age,
shorter time since diagnosis, lower level of perceived social
support and a diagnosis of ovarian cancer. For both IES-I and
IES-A, none of the predictor variables retained in the final
model showed significant interaction with time. For full over-
view over the mixed linear regression analyses for IES-I and
IES-A, see online Supplemental Tables S1 and S2.
Discussion
We found that women who chose BRCA1/2 genetic testing
shortly after a diagnosis of breast- or ovarian cancer had
mean levels of intrusion and avoidance in the moderate
range both before and after genetic testing, with a statistical
significant decrease during a mean time of 7.5 months fol-
low-up. Younger age, shorter time since diagnosis, a diagno-
sis of ovarian cancer, lower levels of social support, higher
levels of decisional conflict, and living with a partner, pre-
dicted higher levels of distress.
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The majority of the participants had a high level of educa-
tion, were working and living with a partner. In addition,
they reported a high average level of perceived social
support. This may indicate that the participants represent a
self-selected group of resourceful women. We know from
previous studies that patients seeking traditional genetic
counseling for hereditary cancer are highly selected and
resourceful [7,8]. The same tendency of self-selection might
have occurred in our study. The finding of low levels of deci-
sional conflict may, not surprisingly, reflect that those with
higher levels of decisional conflict declined genetic testing
and/or to answer the questionnaires.
The mean levels of intrusion and avoidance symptoms in
the present study were in the moderate range (IES subscale
scores 9–19) at all measurements, with mean IES scores rang-
ing from 14.6 (IES-I) and 12.7 (IES-A) at T1 to 9.7 (IES-I and
IES-A) at T3. The change in mean IES-I score from T1 to T3 is
of a magnitude (14.9% of the total IES-I scale) which may
indicate a clinical significant reduction in intrusion during a
mean follow-up of 7.5 months. Our results are in line with
previous reports on patients newly diagnosed with breast
cancer [12,16]. Wevers et al. [16] found in their study of
breast cancer patients at high risk of hereditary breast cancer
mean levels of IES-I at 18.6–18.7 before surgery, and
11.8–12.4 at 6 months follow-up. The corresponding IES-A
scores were 14.0–15.0 before surgery and 10.1–10.5 at
6 months follow-up [16]. In a large study of more than 3000
women with breast cancer unselected for hereditary cancer
Table 1. Baseline variables for the study population.
Diagnostic group
Breast
cancer, N¼ 259
Ovarian
cancer, N¼ 50
All
respondents,
N¼ 309
Continuous variables Mean (SD) Mean (SD) Mean (SD)
Age, years 55.7 (11.5) 58.3 (11.4) 56.1 (11.5)
Time from diagnosis to T1a, days 45 (72) 156 (259) 63 (129)
Time from T1 to T2b, days 52 (48) 46 (21) 51 (46)
Time from T1 to T3c, days 226 (39) 225 (30) 226 (38)
DCSd, range: 0–100 19.7 (15.2) 15.3 (13.3) 19.0 (15.2)
ISEL, range: 1–4 3.46 (0.46) 3.46 (0.48) 3.46 (0.47)
Categorical variables
Categories N (%) N (%) N (%)
Education
Primary school 42 (16.2) 8 (16.0) 50 (16.2)
High school 91 (35.1) 24 (18.0) 115 (37.2)
University 121 (46.7) 17 (34.0) 138 (44.7)
Missing 5 (1.9) 1 (2.0) 6 (1.9)
Employed 161 (62.2) 28 (56.0) 189 (61.2)
Missing 4 (1.5) 1 (2.0) 5 (1.6)
Having biological children 228 (88.0) 44 (88.0) 272 (88.0)
Missing 4 (1.5) 0 (0.0) 4 (1.3)
Living with a partner 180 (69.5) 38 (76.0) 218 (70.6)
Missing 3 (1.2) 0 (0.0) 3 (1.0)
Detection method
Screen-detected 106 (40.9) 0 (0.0) 106 (34.3)
Symptomatic 137 (52.9) 50 (100) 187 (60.5)
Other 16 (6.2) 0 (0.0) 16 (5.2)
Stagee
I 123 (47.5) 4 (8.0) 127 (41.1)
II 108 (41.7) 9 (18.9) 117 (37.9)
III 21 (8.1) 23 (46.0) 44 (14.2)
IV 7 (2.7) 13 (26.0) 20 (6.5)
Unknown 0 (0.0) 1 (2.0) 1 (0.3)
DCS category
Low (0–24) 150 (59.1) 35 (70.0) 185 (60.9)
Intermediate (25–37.5) 75 (29.5) 9 (18.0) 84 (27.6)
High (>37.5) 29 (11.4) 6 (12.0) 35 (11.5)
Post-test genetic counseling
Not offered 156 (60.2) 18 (36.0) 174 (56.3)
Offered, not accepted/received 34 (13.2) 8 (16.0) 42 (13.6)
Offered and received 69 (26.6) 24 (48.0) 93 (30.1)
BRCA1/2 mutation found 6 (2.3) 9 (18.0) 15 (4.9)
FDR with breast or ovarian cancer 56 (21.6) 3 (6.0) 59 (19.1)
FDR with other cancer 86 (33.2) 20 (40.0) 106 (34.3)
Sociodemographic and clinical characteristics of the 309 participants in a study of psychosocial aspects of genetic testing
in women newly diagnosed with breast or ovarian cancer in western Norway between September 2012 and April 2015
(the DNA-BONus study).
SD: standard deviation; T1/T2/T3: successive time points for questionnaires in the study; DCS: Decisional Conflict Scale;
ISEL: Interpersonal Support Evaluation List; FDR: first degree relative.
aFive missing breast cancer, one missing ovarian cancer; b233 valid breast cancer, 39 valid ovarian cancer; c218 valid
breast cancer, 41 valid ovarian cancer; d5 missing breast cancer; ebreast cancer stage according to Union for
International Cancer Control (UICC), ovarian cancer stage according to International Federation of Gynecology and
Obstetrics (FIGO).
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risk, O’Connor et al. [12] reported mean scores of IES-I to be
10.1 and 7.8, 3 months and 15 months after surgery, respect-
ively. The mean scores of IES-A in the same study were 10.0
and 8.4, 3 months and 15 months after surgery, respectively
[12]. Like in these previous reported studies, the IES-scores in
our study showed a statistical significant decline with time.
These findings are also in line with our previous study on
persons undergoing genetic testing for hereditary breast or
ovarian cancer, with the highest scores of both intrusion and
avoidance before genetic testing (mean IES-I: 12.4, mean IES-
A: 9.2), and statistical significant lower scores after disclosure
of the genetic test result (mean IES-I: 9.6, mean IES-A: 7.7)
[7]. Although the mean scores were in the moderate range it
should be noted that in our study one-third of the patients
had intrusion scores in the severe range and one-fourth had
avoidance scores in the severe range, at inclusion. A diagno-
sis of breast or ovarian cancer is a potential life-threatening
event, and receiving the diagnosis is associated with high
levels of distress [12,13]. However, adjustment to the new
situation takes place quite immediately, and the proportion
of patients with higher levels of distress decreases with time
[27], as demonstrated in our study.
A high level of distress has a negative impact on the
patient’s ability to receive and remember information and
can lead to lower adherence and compliance to treatment
and follow-up [17]. Identification of patients with higher lev-
els of intrusion and avoidance is therefore of interest to
ensure better health care for these patients. Our study con-
firms the significance of young age as a predictor of intru-
sion and avoidance symptoms after a diagnosis of cancer.
Consistent with findings in previous studies in patients with
breast or ovarian cancer [12,14,16], we also found that the
level of cancer-related distress is inversely correlated to time
since diagnosis.
Looking at the two different cancer types in our study
group, patients with ovarian cancer had higher levels of
both intrusion and avoidance symptoms as compared to
patients with breast cancer. This may reflect the severity of
the ovarian cancer disease, which was more often diagnosed
at an advanced stage. There are few studies in the literature
Table 2. Levels of IES intrusion and IES avoidance.a
Time point: subscale
At inclusion
(T1)
One week after disclosure
of genetic test result
(T2)
Six months after disclosure
of genetic test result
(T3)
IES-Intrusion (scale 0–35), N 308 277 257
Mean score (SEM) 14.6 (0.5) 12.1 (0.6) 9.7 (0.5)
Median (IQR) 14.0 (7.0–22.0) 9.0 (4.0–19.0) 7.0 (4.0–14.0)
Grouped, N (%)
Minor, score 0–8 102 (33.1) 132 (47.7) 147 (57.2)
Moderate, score 9–19 107 (34.7) 77 (27.8) 74 (28.8)
Severe, score 20 99 (32.1) 68 (24.5) 36 (14.0)
IES-avoidance (scale 0–40), N 309 277 256
Mean score (SEM) 12.7 (0.5) 10.2 (0.5) 9.7 (0.5)
Median (IQR) 11.0 (6.0–19.0) 8.0 (4.0–15.0) 8.0 (3.0–15.0)
Grouped, N (%)
Minor, score 0–8 117 (37.9) 142 (51.3) 138 (53.9)
Moderate, score 9–19 119 (38.5) 91 (32.9) 77 (30.1)
Severe, score 20 73 (23.6) 44 (15.9) 41 (16.0)
Distribution of IES subscales at different time points in 309 women undergoing genetic BRCA1/2 testing when newly diagnosed
with breast or ovarian cancer in western Norway between September 2012 and April 2015.
IES¼ Impact of Event Scale (Horowitz et al. 1979); SEM: standard error of the mean; IQR: interquartile range.
aAll paired comparisons between the time points were statistically significant at the 0.001-level using the paired t-test or the
paired Wilcoxon/Mann–Whitney test except for the comparison of T2 and T3 for IES-avoidance.
Table 3. Simplified linear regression models of IES intrusion and avoidance subscales.
Variables IES-intrusion IES-avoidance
Categories b 95% CI p value b 95% CI p value
Intercept 34.35 (25.59, 43.10) <.001 38.50 (30.48, 46.53) <.001
Ovarian versus breast cancer 3.53 (1.10, 5.96) .005 3.36 (1.03, 5.69) .005
Age per 10 years 1.80 (2.58, 1.03) <.001 1.02 (1.75, 0.30) .006
Months from diagnosis to T1 0.25 (0.46, 0.05) .017 0.21 (0.41, 0.01) .039
DCS per 10 points score 0.67 (0.10, 1.24) .022
ISEL 3.71 (5.60, 1.83) <.001 5.86 (7.62, 4.09) <.001
Questionnaire time point <.001 <.001
T1 0.00 Reference 0.00 Reference
T2 2.38 (3.24, 1.52) 2.19 (2.96, 1.41)
T3 4.73 (5.75, 3.70) 2.67 (3.57, 1.78)
Living with a partner 2.56 (0.639, 4.48) .010
Final model of mixed linear regression analyses for IES subscales in 309 women undergoing genetic
testing when newly diagnosed with breast or ovarian cancer in western Norway between September
2012 and April 2015.
b: estimated regression coefficient; CI: confidence interval; p value: from F-test; IES: Impact of Event
Scale (0–35/40); DCS: Decisional Conflict Scale (0–100); ISEL: Interpersonal Support Evaluation List
(1–4); T1: time of inclusion; T2: one week after disclosure of genetic test result; T3: six months after
disclosure of genetic test result.
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comparing psychological distress in patients with breast can-
cer and ovarian cancer directly, but our results are consistent
with a recent meta-analysis where PTSD was reported more
prevalent among survivors of gynecological cancer compared
to survivors of breast cancer [33].
The protective effect of perceived social support on dis-
tress following a cancer diagnosis was confirmed in our
study, and the effect was evident at all time points. Our find-
ings show that this general resource also plays an important
role in how a person copes with specific life events such as
receiving a cancer diagnosis and simultaneously undergoing
genetic testing. One should be aware that the protective
effect is associated with perceived social support—as it is
experienced by the person herself. In the light of this, our
finding of increased intrusion symptoms in women living
with a partner is interesting.
Previous research has shown diverging results when it
comes to the effect of marriage or marriage-like relationship
on psychological distress in patients with cancer [13,25,26,34].
Studies that have looked thoroughly into the complexity of
this matter have revealed that the quality of the intimate rela-
tionship is decisive for whether having a partner has a posi-
tive or negative impact on the psychological distress in
patients with cancer [35]. Furthermore, there seems to be a
gender effect: while men with cancer are less likely to
develop symptoms of psychological distress if they are mar-
ried, female cancer patients have lower levels of psycho-
logical distress if they are not married [36]. In addition, both
breast and ovarian cancer affect organs inevitable connected
to female body image and sexuality, a fact that may be of
importance for the observed difference between women with
and without a cohabitating partner in our study.
In this study, traditional pretest genetic counseling was
not given. Since genetic counseling has been shown to
reduce decisional conflict regarding genetic testing [10], the
finding that higher levels of decisional conflict at baseline
predicted more intrusive thoughts both at baseline and at
follow-up measurements is worth noting. Patients with
higher levels of decisional conflict could benefit from more
counseling and support in the decision making process, with
potential both to reduce the level of distress, and to increase
the uptake of genetic testing. However, integration of gen-
etic testing into busy cancer clinics requires alternative ways
of providing such support. For this purpose, some education
and information resources already exist, and new tools for
decision-making support are under development [37]. More
use of web-based technology and applications based on arti-
ficial intelligence, could contribute to more personalized
information and counseling of patients undergoing gen-
etic testing.
A limitation to our study is that it was not possible to col-
lect information about the patients who declined genetic
testing, due to ethical regulations. The participants in our
study may therefore not be representative for all patients
with newly diagnosed breast or ovarian cancer. Furthermore,
the number of mutation carriers was too low to detect a
potential effect of a positive gene test result on the levels of
intrusion and avoidance.
In summary, our study documents a moderate level of
cancer-related distress in women having genetic BRCA1/2
testing without pretest genetic counseling shortly after a
diagnosis of breast- or ovarian cancer, and that the level of
distress decreases with time. Although this indicates that a
simplified procedure for genetic testing of large patient
groups with newly diagnosed cancer is feasible, we identified
possible predictor factors for experiencing increased cancer-
related distress: younger age, less perceived social support,
higher levels of decisional conflict, and being a woman living
with a partner. Clinicians should be aware of this when offer-
ing diagnostic genetic testing, to make sure that the more
vulnerable patients do not miss the opportunity for personal-
ized treatment.
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